Patent · US Active

Combinations and uses thereof

US11224654B2 · kind B2 · utility

1Cited by

14References

18Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Jan Endell · Munich, DE
Mark Winderlich · Munich, DE
Rainer Boxhammer · Aying, DE

Key dates

Filing date	Aug 18, 2016
Grant date	Jan 18, 2022
Priority date	—
Expiry date	Jun 14, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.